At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 80 enrolled
Drug / intervention
Etrasimod +2 moredrug
Likely dose
Etrasimod 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study, With a 28-Week Open-Label Extension, to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Alopecia Areata
In Brief
A Phase 2 clinical trial evaluating Etrasimod and Placebo for Alopecia Areata. Completed, enrolled 80 participants across 42 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of etrasimod monotherapy (2 milligrams \[mg\] and 3 mg) in participants with moderate-to-severe alopecia areata (AA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlopecia Areata
CountriesCanada, United States
CollaboratorsArena is a wholly owned subsidiary of Pfizer
Timeline
Phase 2CompletedFinished
202120222023202420252026
Enrollment StartJul 2020
First PostedSep 2020
Primary CompletionJun 2023
TodayJul 2026
First PostedSep 21, 2020
Enrollment StartJul 29, 2020
Primary CompletionJun 7, 2023
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 5.8 years ago
Interventions
Etrasimoddrug
Etrasimod 2 mg tablet by mouth, once daily
Etrasimoddrug
Etrasimod 3 mg (1 mg and 2 mg tablets) by mouth, once daily
Placebodrug
Etrasimod matching placebo tablet by mouth, once daily